Unicycive Therapeutics UNCY 深 沪
交易中 07-06 11:01:42 美东时间
5.42
-0.310
-5.41%
华盛通- 最 高5.91
- 今 开5.80
- 成交量 83.15万股
- 最 低 5.31
- 昨 收 5.73
- 总市值 1.48亿
- 52周最高 8.74
- 市盈率 静 --
- 换手率 3.04%
- 52周最低 3.71
- 委 比 -33.77%
- 总股本 2739.30万
- 历史最高 87.30
- 量 比 0.55
- 振 幅 10.47%
- 历史最低 2.02
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
美股夜盘 | 707 Cayman Holdings涨154.16%，Globavend Holdings Ltd.涨22.92%
因立夫涨-43.13%；柏雅国际涨-17.28%；Core Al涨-6.95%
07-01 08:05
Unicycive plummets following second CRL for OLC for hyperphosphatemia
Unicycive Therapeutics is down ~37% in Tuesday afternoon trading after announcing it has received a Complete Response Letter from the FDA for its resubmitted NDA for oxylanthanum carbonate (OLC) to tr...
07-01 02:05
Why Is Unicycive Therapeutics Stock Falling Tuesday?
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on Monday said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its resubmitted New Drug Application (NDA) seeking approval of oxylanthanum carbonate (OLC) for hyperphosphatemia in patients with chronic kidney disease (C...
06-30 23:04
Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Applicat...
06-30 19:10
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding the resubmitted NDA for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The FDA did not raise concerns about clinical efficacy or safety data and did not request additional data. The CRL was based on previously identified deficiencies at a third-party manufacturing vendor, which the FDA has not yet ...
06-30 11:05
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
While there are already several drugs already approved to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, Shalabh Gupta isn't fazed. As CEO of Unicycive Therapeutics...
06-22 21:56
Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026
Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026 Unicycive Therapeutics held its annual shareholder meeting on June 19, 2025. Shareholders selected three director nominees to serve through the 2027 annual meeting. Shareholders ratified Grassi & Co. CPAs, P.C. as i
06-22 18:06
